The company buys in a PI3Kα and mTOR combo.
ApexOnco Front Page
Recent articles
Gilead opting against IDE397 is still good news for Ideaya.
Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.
Party season approaches; but first, conferences.
Two cast-offs comprise the private group's attempts to hit PARP1 and PARP7.
A $1bn buyout gives Roche more allogeneic Car-T projects, plus non-viral gene therapy contenders.
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
But could toxicity be holding back filing plans?
